Comparative Pharmacology
Head-to-head clinical analysis: PRISMASOL B22GK 2 0 IN PLASTIC CONTAINER versus PRISMASOL BK 0 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRISMASOL B22GK 2 0 IN PLASTIC CONTAINER versus PRISMASOL BK 0 3 5 IN PLASTIC CONTAINER.
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER vs PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prismasol B22GK 2/0 is a solution used in continuous renal replacement therapy (CRRT) to correct electrolyte imbalances and remove waste products. It provides bicarbonate as a buffer via metabolism of lactate or acetate, and contains electrolytes to maintain homeostasis.
PrismaSol is a sterile solution containing electrolytes and bicarbonate buffer, used in continuous renal replacement therapy (CRRT) to correct fluid and electrolyte imbalances and acid-base disturbances. It acts as a replacement fluid to maintain electrolyte and acid-base homeostasis by providing physiologic concentrations of electrolytes and a bicarbonate buffer.
Continuous renal replacement therapy (CRRT): prescription as per institutional protocol, typically 2000-2500 mL/h effluent rate (dialysate + replacement fluid) for adults. Peritoneal dialysis: 2-3 L exchanges, 4-5 times daily or cycler. Intravenous infusion only via CRRT or as dialysate/replacement fluid.
Continuous renal replacement therapy (CRRT): 2000 mL bag, flow rate 1000-2000 mL/h (dose tailored to target electrolyte balance and acid-base status). For continuous ambulatory peritoneal dialysis (CAPD): 2000 mL per exchange, 4 exchanges per day (individualized). Intravenous or intraperitoneal route.
None Documented
None Documented
Not applicable; PRISMASOL B22GK 2/0 is a dialysate solution for CRRT. Components (glucose, electrolytes, lactate/bicarbonate) are continuously removed and replaced. For buffer conversion: lactate half-life ~5 minutes (hepatic metabolism to bicarbonate).
Not applicable as the drug is not systemically present; half-life refers to solutes in the patient's blood during CRRT, which is determined by the therapy and patient factors, not the solution.
Renal (100%); eliminated unchanged by ultrafiltration and diffusion during continuous renal replacement therapy (CRRT). Biliary/fecal: negligible.
Not applicable; PRISMASOL BK 0/3.5 is a renal replacement therapy solution not systemically absorbed. Solutes are removed via continuous renal replacement therapy (CRRT) circuit, with clearance dependent on operational parameters.
Category C
Category C
Dialysis Solution
Dialysis Solution